Perfusion measures were compared between VSASL and DSC methods at 1.5T in 28 patients with treated high-grade glioma assigned into 2 groups: “tumor” (with detectable enhancing tumor, n=9) and “non-tumor” (without detectable tumor, n=19). All measures (rCBF and tSNR from VSASL, rCBV and rCBF from DSC) showed significant difference between “tumor” and “non-tumor” groups allowing reliable discrimination. In general, there was moderate to excellent agreement and correlation between these measures derived from VSASL vs. DSC. Hence, VSASL has potential to serve as a viable non-invasive alternative to DSC perfusion in the clinical disease surveillance without the need for exogenous contrast.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords